With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.